Re: Placebo or Standard of Care
in response to
by
posted on
Nov 02, 2019 10:14AM
accchhhhh,,,,we discussed this issue around the two statins and the cummulative effect on the TLD for the past 4 years. It is what it is,,,,,I remember we beat the issue to death at the time as we had anxiety over it then and seems as well now!,,,,,,the milk has been spilled and looking back is of no use to either patients or shareholders. Let the data speak for itself as our senior managment team has asked and graciously given us a heads up on. If they didnt do this for us the sell side would have created a blood bath. For me,,,the request to sit on our hands is a very optimistic indication for Nov. 16th and beyond.
Do we have to home run all the data?..Of course not. As shareholders we are being too greedy in this infant search of a holy grail around such diseases, similar to DMcC with the business side of this science,,,,,we only need one indication to have a meaningful future for all parties who have a vested interest in the control of inflammatory disease and or for financial gain.
Stay strong and long on this investment is probably good advice. I believe our team has respectfully implied that!,,,,,,,,,,,,,,jmo